SCHEMBL5845640

SCHEMBL5845640

CCc1nc(C2CCC(C(C)(C)C)CC2)n2nc(-c3cccc4ccccc34)[nH]c(=O)c12

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 11/20 0.47
PDE1A P54750 6/20 0.47
PDE1B Q01064 6/20 0.47
PDE1C Q14123 6/20 0.47
BRD4 O60885 1/20 0.36
CREBBP Q92793 1/20 0.36
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
KDM4E B2RXH2 1/20 0.33
KHK P50053 1/20 0.33
GABRA1 P14867 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
KMT2A Q03164 1/20 0.32
ALOX15 P16050 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5845638 1.00 PDE5A (0.47) PDE5APDE1APDE1BPDE1CBRD4
SCHEMBL5883924 0.92 PDE5A (0.47) PDE5APDE1APDE1BPDE1CBRD4
SCHEMBL5884015 0.90 PDE5A (0.49) PDE5APDE1APDE1BPDE1CBRD4
SCHEMBL5883877 0.90 PDE5A (0.58) PDE5APDE1APDE1BPDE1CBRD4
SCHEMBL5883861 0.90 PDE5A (0.55) PDE5APDE1APDE1BPDE1CBRD4
SCHEMBL5729561 0.87 PDE5A (0.42) PDE5APDE1APDE1BPDE1CPDE3B
SCHEMBL5845859 0.86 PDE5A (0.44) PDE5APDE1APDE1BPDE1CPDE3B
SCHEMBL5845866 0.86 PDE5A (0.44) PDE5APDE1APDE1BPDE1CPDE3B
SCHEMBL5883905 0.84 PDE5A (0.46) PDE5APDE1APDE1BPDE1CBRD4
SCHEMBL5730920 0.83 PDE5A (0.44) PDE5APDE1APDE1BPDE1CPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115602-B2 Heterocycles 3 BAYER AKTIENGESELLSCHAFT (DE) 2006-10-03 US disclosed
US-20050065153-A1 Novel heterocycles 3 BAYER AKTIENGESELLSCHAFT (DE) 2005-03-24 US disclosed
EP-1399447-A1 IMIDAZOTRIAZINONES DERIVATIVES AND THEIR USE AGAINST INFLAMMATORY PROCESSES AND/OR IMMUNE DISEASES Bayer HealthCare AG (DE) 2004-03-24 EP disclosed
US-20030139415-A1 Novel heterocycles 3 BAYER HEALTHCARE AKTIENGESELLSCHAFT (DE) 2003-07-24 US disclosed
WO-2002098879-A1 IMIDAZOTRIAZINONES DERIVATIVES AND THEIR USE AGAINST INFLAMMATORY PROCESSES AND/OR IMMUNE DISEASES BAYER HEALTHCARE AG (DE) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139415-A1 Novel heterocycles 3 NFATC1, NOD2, NFKBIA PDE5A 1993/4885PDE1A 3380/4885PDE1B 3869/4885
US-20050065153-A1 Novel heterocycles 3 NFATC1, NOD2, NFKBIA PDE5A 1993/4885PDE1A 3380/4885PDE1B 3869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.